Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03821272 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03821272 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 17 participants.
The verdict
NCT03821272, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study has been designed to evaluate the safety and efficacy of giving seven injections of PepCan or placebo over approximately a 24-month period in subjects with head and neck cancers who achieved remission. PepCan may prove to be beneficial in treating many stages of HPV-related malignancies starting from infection to cancer. Safety, efficacy in terms of reduced cancer recurrence, immunological responses and profiles, and gut microbiome changes will be assessed.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PepCan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2025-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03821272
The ClinicalTrials.gov registry entry for NCT03821272 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03821272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03821272 about?
NCT03821272 is a clinical study titled "A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients". This study has been designed to evaluate the safety and efficacy of giving seven injections of PepCan or placebo over approximately a 24-month period in subjects with head and neck cancers who achieved remission. PepCan may prove to be beneficial in treating many stages of HPV-related malignancies s...
What is the current status of trial NCT03821272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-11-13. Estimated completion is 2025-02-03.
What interventions are being tested in trial NCT03821272?
The interventions under investigation include: Placebo (BIOLOGICAL), PepCan (BIOLOGICAL).
Who is sponsoring clinical trial NCT03821272?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.